secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001157523-22-000551
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River Q1 revenue $913.9M (+10.8%), GAAP EPS $1.81, non-GAAP EPS $2.75
-----------------------------------------------------------------------------

- Q1 revenue $913.9M (+10.8% YoY); organic growth 9.4%; GAAP net income $93.0M (+51.2%); non-GAAP net income $141.1M (+9.3%).
- Segment revenue: RMS $176.5M (flat), DSA $544.3M (+8.6%), Manufacturing $193.1M (+31.8% driven by CDMO acquisitions).
- 2022 guidance updated: reported revenue growth raised to 13.5%-15.5% (from 13-15%); organic growth unchanged 12.5%-14.5%; non-GAAP EPS reaffirmed $11.50-$11.75.
- DSA segment reported record booking activity and strong backlog growth, with studies booked into 2023.
- Foreign currency reduced reported revenue growth by 1.7%; acquisitions contributed 4.7%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000115752322000551/0001157523-22-000551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000115752322000551/a52706413.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-000551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer